Investigation of combined gel antimicrobial activity for the treatment of oral cavity infectious-inflammatory diseases

Topicality. Treatment of periodontal inflammatory disease is one of the most pressing problems of dentistry. According to the modern point of view, inflammatory periodontal diseases are infectious chronic inflammatory diseases, that is why to normalize oral microflora is a continuous condition of their rational therapy. In chronic gingivitis and periodontitis the number of anaerobic bacteria strains increases to 70-80 %, whereas in normal their number does not exceed 20-30 %. This explains the feasibility of topical use of anaerobic drugs in the treatment of inflammatory periodontal diseases.Aim. To substantiate and to study the antimicrobial activity of the combined gel intended for the treatment of oral cavity infectious-inflammatory diseases.Materials and methods. We used biological pharmacopoeial method of research (study of antimicrobial preservatives effectiveness).Results and discussion. According to the results of studies of antimicrobial action in the bacterial inoculation of the tested samples of the gel with serial number 10219 (metronidazole benzoate – 1.60 g; miramistin – 0.50 g; hyaluronic acid – 0.20 g) and serial number 40219 (metronidazole benzoate – 1.60 g; miramistin – 0.50 g). At specified intervals, viable aerobic microorganisms S. aureus, P. aeruginosa and the yeast and mold fungi C. albicans, A. brasiliensis were not detected, and the logarithm for their decrease was more than 5. However, in the studied series 20219 (metronidazole benzoate – 1.00 g; miramistin – 0.50 g), at 14 and 28 days after inoculation from the test samples for appropriate nutrient media, and in series 30219 (metronidazole benzoate – 1.20 g; miramistin – 0.20 g) for 14 days, there was a significant increase in the colonies of all microorganisms compared to their number at the previous control point. There was no logarithm for reducing the number of viable aerobic microorganisms and yeast and mold fungi. Therefore, studies have shown that the developed gel with serial numbers 10219 and 40219 withstand the antimicrobial efficacy test in accordance with the requirements of SPhU *, section 5.1.3, for oromucosal drugs. Therefore, for further studies we will use the specified model samples.Conclusions. We theoretically and experimentally substantiated the development of the combined gel, proved the concentration of active pharmaceutical ingredients with regard to its antimicrobial action.